Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for EBS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2004. Start Trial.
Date Value
June 30, 2026 341.40M
March 31, 2026 523.10M
December 31, 2025 522.60M
September 30, 2025 582.50M
June 30, 2025 536.20M
March 31, 2025 552.70M
December 31, 2024 482.80M
September 30, 2024 508.40M
June 30, 2024 386.30M
March 31, 2024 663.90M
December 31, 2023 649.30M
September 30, 2023 697.20M
June 30, 2023 956.30M
March 31, 2023 1.203B
December 31, 2022 1.388B
September 30, 2022 1.449B
June 30, 2022 1.513B
March 31, 2022 1.575B
December 31, 2021 1.612B
September 30, 2021 1.523B
June 30, 2021 1.544B
March 31, 2021 1.523B
December 31, 2020 1.447B
September 30, 2020 1.252B
June 30, 2020 1.199B
Date Value
March 31, 2020 1.075B
December 31, 2019 1.088B
September 30, 2019 1.035B
June 30, 2019 988.90M
March 31, 2019 987.50M
December 31, 2018 1.011B
September 30, 2018 966.65M
June 30, 2018 938.35M
March 31, 2018 881.28M
December 31, 2017 912.34M
September 30, 2017 663.71M
June 30, 2017 620.60M
March 31, 2017 610.42M
December 31, 2016 596.20M
September 30, 2016 547.62M
June 30, 2016 672.67M
March 31, 2016 666.98M
December 31, 2015 660.02M
September 30, 2015 605.31M
June 30, 2015 562.25M
March 31, 2015 537.88M
December 31, 2014 553.20M
September 30, 2014 513.14M
June 30, 2014 487.77M
March 31, 2014 477.50M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Exelixis, Inc. 1.844B
Capricor Therapeutics, Inc. 246.22M
ADMA Biologics, Inc. 408.21M
Akebia Therapeutics, Inc. 25.02M
Arcutis Biotherapeutics, Inc. 220.58M

Shareholders Equity (Quarterly) Related Metrics